Becton Dickinson stock (US0718131099): Antitrust case survives dismissal

A Pennsylvania federal court denied dismissal of an antitrust lawsuit against Becton Dickinson by Tela Bio, allowing the case to proceed as of May 13, 2026.

Becton Dickinson faces an ongoing antitrust lawsuit after a Pennsylvania federal court refused to dismiss claims brought by Tela Bio Inc. on May 13, 2026. The case centers on allegations related to hernia mesh products, according to Law360 as of May 13, 2026. This development keeps legal pressures on the medical device giant amid its US market operations.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Becton Dickinson and Company
• Sector/industry: Medical devices and diagnostics
• Headquarters/country: United States
• Core markets: North America, Europe, Asia
• Key revenue drivers: Infusion therapy, diagnostics, surgical instruments
• Home exchange/listing venue: NYSE (BDX)
• Trading currency: USD

Becton Dickinson: core business model

Becton Dickinson and Company develops, manufactures and sells medical devices, instrument systems and reagents worldwide. The company operates through segments including BD Medical, BD Life Sciences and BD Interventional. Products range from syringes and catheters to diagnostic systems used in hospitals and labs, serving healthcare providers and researchers across the US and globally. This diversified portfolio supports steady demand in the healthcare sector.

Main revenue and product drivers for Becton Dickinson

Key revenue comes from infusion therapy devices, diagnostic platforms and surgical products. In recent periods, growth has been driven by demand for safety-engineered needles and automated lab solutions. The US market represents a significant portion of sales, with exposure to hospital spending and biotech research, according to company reports. Analyst forecasts project revenue growth of around 0.3% annually over the next three years, with earnings per share expanding by 9.8% per annum, as noted by Simply Wall St.

Industry trends and competitive position

The medical device industry faces trends like digital health integration and supply chain resilience post-pandemic. Becton Dickinson holds a strong position in vascular access and molecular diagnostics, competing with firms like Medtronic and Thermo Fisher. Its scale provides advantages in R&D and global distribution, particularly relevant for US investors tracking healthcare innovation and regulatory dynamics.

Why Becton Dickinson matters for US investors

Listed on the NYSE under ticker BDX, Becton Dickinson offers US investors exposure to essential medical technologies amid aging demographics and rising healthcare costs. The company's products are integral to US hospitals and labs, linking its performance to domestic economic health and Medicare policies.

Conclusion

The recent court decision to let the antitrust case proceed adds a layer of legal scrutiny for Becton Dickinson, while its core operations in medical devices remain robust. Investors monitor such developments alongside product demand and analyst views, which see potential upside with average price targets around $213 from recent reports. The stock's role in US healthcare underscores its relevance amid ongoing industry shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.